Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...

The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo ... governance ESG risks (such as off-label marketing or litigation related ...

Vabysmo keeps expanding market share in all ... We are waiting for additional data from the ongoing label extension and with the benefit of that additional data and in close alignment with ...

The FDA approved a label expansion of Dupixent for the treatment ... under pressure for some time now due to competition from Vabysmo. We note that Vabysmo's uptake has been outstanding.

“So we did discuss about various treatment options. We discussed about off-label Avastin to Eylea, Eylea HD, Vabysmo, and after discussing with the patient and getting approved for ...

The rest of it, with respect to any other loading of an anti-VEGF, whether it's off-label Avastin, Lucentis, Vabysmo, the 3 monthly doses, you wouldn't expect a patient to respond any differently ...

Eylea’s sales were under pressure in recent quarters due to competition from Vabysmo. Sales are likely ... and prurigo nodularis. The recent label expansion of the drug in the COPD indication ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% from ...

“So when we talk about the available treatment options for wet macular degeneration, we are really lucky that we have so many options in today's day, ranging from Avastin off-label, to many of ...